Hemogenyx Regulatory News (HEMO)

Silver Falcon Plc

("SILF" or "the Company")

Result of General Meeting

Silver Falcon Plc, (LSE: SILF), which has agreed to acquire the biotechnology company Hemogenyx Pharmaceuticals Limited ("Hemogenyx"), announces that following a General Meeting of the Company today all resolutions were duly approved by shareholders, including in relation to the waiver of Rule 9 of the Takeover Code and the Placing and Subscription. 

Accordingly, the Acquisition and the related Placing and Subscription will complete tomorrow, 5 October 2017, subject only to the readmission of the enlarged share capital to the standard listing segment of the Official List and to trading on the main market for listed securities of the London Stock Exchange ("Admission"), which is expected to commence at 8.00 a.m. on 5 October 2017.

On Admission, the Company's total issued share capital will consist of 356,042,854 Ordinary Shares of £0.01 each. The Company holds no Ordinary Shares in treasury. The above figure (356,042,854) may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Hemogenyx Pharmaceuticals plc under the FCA's Disclosure Guidance and Transparency Rules.

The Company will trade under the new company name of Hemogenyx Pharmaceuticals Plc and the Company's new London Stock Exchange TIDM ticker symbol will be HEMO and its ISIN will remain as GB00BYX3WZ24.

In addition, the Company's new website address will be www.hemogenyx.com

Enquiries: